{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:15:59Z","timestamp":1792498559214,"version":"4.5.0"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","award":["IIRGBR000297"],"award-info":[{"award-number":["IIRGBR000297"]}],"id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Society for Mucopolysaccharide Diseases (MPS Society)"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0193550","type":"journal-article","created":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T20:19:38Z","timestamp":1522959578000},"page":"e0193550","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Phenotype and biochemical heterogeneity in late onset Fabry disease defined by N215S mutation"],"prefix":"10.1371","volume":"13","author":[{"given":"L.","family":"Lavalle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. S.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ebrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ramaswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. B.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,4,5]]},"reference":[{"key":"ref1","unstructured":"Mehta A. &amp; Hughes DA. Fabry disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews\u00ae. 2002 Aug 5 [updated 2017 Jan 5]."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","article-title":"Fabry disease in childhood","volume":"144","author":"RJ Desnick","year":"2004","journal-title":"J Pediatr"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"JM Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11940-016-0414-5","article-title":"Fabry disease: recognition, diagnosis, and treatment of neurological features","volume":"18","author":"M. Ranieri","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref5","article-title":"Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect","author":"JL Park","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref6","article-title":"Is it Fabry disease?","author":"R Schiffmann","year":"2016","journal-title":"Genet Med"},{"key":"ref7","article-title":"Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene","author":"CM Eng","year":"1994","journal-title":"Hum Mutat"},{"issue":"3","key":"ref8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/BF03401671","article-title":"Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes","volume":"3","author":"CM Eng","year":"1997","journal-title":"Mol Med"},{"key":"ref9","article-title":"The alpha-galactosidase A p.Arg118Cys variant does not cause Fabry disease phenotype: data from individual patients and family studies","author":"S Ferreira","year":"2015","journal-title":"Mol Genet Metab"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","article-title":"Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene","author":"I Redonnet-Vernhet","year":"1996","journal-title":"J Med Genet"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1006\/bbrc.1999.0310","article-title":"Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches","volume":"257","author":"DP Germain","year":"1999","journal-title":"Biochem Biophys Res Commun"},{"key":"ref12","article-title":"Clinical Characteristics of the GLA N215S Variant and Implications for the Diagnosis and Management of Nonclassic Fabry Disease","author":"C Reuter","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"ref13","article-title":"Natural history of Fabry disease in females in the Fabry Outcome Survey","author":"PB Deegan","year":"2006","journal-title":"J Med Genet"},{"key":"ref14","article-title":"Functional and clinical consequences of novel \u03b1-Galactosidase A mutations in Fabry disease","author":"J Lukas","year":"2015","journal-title":"Hum Mutat"},{"key":"ref15","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease","author":"V Patel","year":"2016","journal-title":"Heart"},{"key":"ref16","unstructured":"Ries M. Gal A. Genotype\u2013phenotype correlation in Fabry disease. In: Mehta A, Beck M, and Sunder-Plassmann G Ries M. Gal A; Fabry Disease: Perspectives from 5 Years of FOS. 2006."},{"key":"ref17","article-title":"Epigenetics and type II diabetes mellitus: underlying mechanisms of prenatal predisposition","author":"JD Sterns","year":"2014","journal-title":"Front Cell Dev Biol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/08035320510028111","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"447","author":"E Young","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"ref19","article-title":"Treatment of Fabry disease: outcome of a comparative trial with algasidase alfa or beta at a dose of 0.2 mg\/kg","author":"AC Vedder","year":"2007","journal-title":"PLoS One"},{"key":"ref20","article-title":"Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa","author":"R Schiffmann","year":"2013","journal-title":"Genet Med"},{"key":"ref21","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","author":"BE Smid","year":"2015","journal-title":"J Med Genet"},{"key":"ref22","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","author":"M Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"ref23","article-title":"Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G&gt;A)","author":"HC Liu","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"ref24","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","author":"A Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1016\/j.cca.2010.07.038","article-title":"How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?","volume":"411","author":"C Auray-Blais","year":"2010","journal-title":"Clin Chim Acta"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/hmg\/2.7.1051","article-title":"Mutation analysis in patients with the typical form of Anderson-Fabry disease","author":"JP Davies","year":"1993","journal-title":"Hum Mol Genet"},{"key":"ref27","first-page":"1186","article-title":"Nature and Frequency of Mutations in the a-Galactosidase A Gene That Cause Fabry Disease","volume":"B3","author":"CM Eng","year":"1993","journal-title":"Am.J.Hum.Genet"},{"key":"ref28","article-title":"Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene","author":"CM Eng","year":"1994","journal-title":"Hum Mutat"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry&apos;s disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"M Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"ref30","article-title":"\u03b1-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease","author":"D Oder","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"RB Devereux","year":"1986","journal-title":"Am J Cardiol"},{"key":"ref32","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy","author":"C Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2010.06.002","article-title":"Deegan P; FOS Investigators. Age adjusting severity scores for Anderson-Fabry disease","volume":"101","author":"DA Hughes","year":"2010","journal-title":"Mol Genet Metab"},{"key":"ref34","first-page":"491","article-title":"The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)\u2014investigation of symptomatic and presymptomatic patients","volume":"75","author":"SH Morgan","year":"1990","journal-title":"Q J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2012.192138","article-title":"Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry","volume":"59","author":"H Gold","year":"2013","journal-title":"Clin Chem"},{"key":"ref36","article-title":"Recommendations for chamber quantification","author":"RM Lang","year":"2006","journal-title":"Eur J Echocardiogr"},{"key":"ref37","unstructured":"National life tables, UK: 2013\u20132015. Office for National Statistics. 2016, 26 Sep. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/20132015\" xlink:type=\"simple\">https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/bulletins\/nationallifetablesunitedkingdom\/20132015<\/ext-link>"},{"key":"ref38","article-title":"Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G&gt;A)","author":"HC Liao","year":"2013","journal-title":"Clin Chim Acta"},{"key":"ref39","article-title":"Fabry disease and the heart","author":"N Seydelmann","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref40","article-title":"Agalsidase benefits renal histology in young patients with Fabry disease","author":"C T\u00f8ndel","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"ref41","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","author":"MD Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"ref42","article-title":"Lyso-Gb3 activates Notch1 in human podocytes","author":"MD Sanchez-Ni\u00f1o","year":"2015","journal-title":"Hum Mol Genet"},{"key":"ref43","article-title":"Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study","author":"M Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"ref44","article-title":"Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease","author":"SM Rombach","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref45","article-title":"Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience with a Highly Prevalent Mutation","author":"TR Hsu","year":"2016","journal-title":"J Am Coll Cardiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0193550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T01:27:39Z","timestamp":1571016459000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0193550"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Shimosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,4,5]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0193550","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,5]]}}}